Adocia (ADOCY) AI Stock Analysis

• Market Cap: $189.77M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 1882.51%
• EPS Growth: 62.37%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 18,298,424
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.37
• Price to Book (P/B): -54.61
• Price to Sales (P/S): 18.10
• P/FCF Ratio: -10.65
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 6.88
• Enterprise Value/Gross Profit: 67.82
• Enterprise Value/Ebitda: 16.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $10.00 ▼(-0.40% Downside)

Adocia's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses, negative equity, and cash flow challenges. Technical analysis provides some support with mixed signals, but the valuation remains unattractive due to a negative P/E ratio and lack of dividends. The absence of earnings call data and notable corporate events leaves the financial difficulties as the most significant factor influencing the score.

Adocia Business Overview & Revenue Model

Company Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

How the Company Makes Money

Adocia generates revenue primarily through partnerships and collaborations with pharmaceutical companies for the development and commercialization of its products. This includes licensing agreements, milestone payments, and royalties on sales of products developed using Adocia's technology. The company's strategic partnerships with larger pharmaceutical firms enable it to leverage their resources and market reach, while also sharing the financial risks associated with drug development. Additionally, Adocia may receive funding through grants or government support aimed at fostering innovation in healthcare.

Adocia Financial Statement Overview

Summary

Adocia faces substantial financial challenges, with persistent losses and liquidity issues. The high gross profit margin is overshadowed by significant operational and financial expenses, resulting in persistent net losses. The negative equity and reliance on debt highlight financial instability. Cash flow difficulties further exacerbate the company's financial position, indicating a need for strategic restructuring and financial management improvements.

Income Statement

Adocia's income statement shows significant challenges with persistent net losses and negative EBIT and EBITDA margins. Although there was a revenue increase from 2023 to 2024, the overall trajectory has been inconsistent. The gross profit margin is relatively high, indicating cost management at the production level, but the net profit margin remains deeply negative, reflecting high operating expenses and financial difficulties.

Balance Sheet

The balance sheet of Adocia reveals a negative stockholders' equity, indicating financial instability and high leverage. The debt-to-equity ratio is unmeasurable due to negative equity, and the company consistently operates with more liabilities than assets. The equity ratio is negative, highlighting significant financial risk and reliance on debt financing.

Cash Flow

Adocia's cash flow statement demonstrates cash flow challenges with negative operating cash flow and free cash flow over the years. The free cash flow growth rate is negative, and the company is heavily reliant on financing activities to sustain operations. While there is some cash generated from financing, it is insufficient to cover negative free cash flows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.32M	2.15M	11.45M	1.44M	841.00K
Gross Profit	8.20M	1.39M	9.61M	180.00K	-616.00K
EBITDA	-6.91M	-19.35M	-3.58M	-19.49M	-20.03M
Net Income	-9.32M	-21.16M	-6.90M	-22.75M	-23.32M
Balance Sheet
Total Assets	27.02M	24.96M	30.61M	30.05M	45.17M
Cash, Cash Equivalents and Short-Term Investments	7.53M	12.96M	17.42M	15.16M	28.11M
Total Debt	11.83M	13.09M	33.21M	34.48M	28.20M
Total Liabilities	30.11M	31.87M	43.58M	43.87M	38.83M
Stockholders Equity	-3.09M	-6.91M	-12.97M	-13.81M	6.33M
Cash Flow
Free Cash Flow	-15.84M	-5.11M	-15.15M	-19.59M	-22.06M
Operating Cash Flow	-15.61M	-4.95M	-14.99M	-19.23M	-21.85M
Investing Cash Flow	-258.00K	-138.00K	21.86M	-361.00K	-204.00K
Financing Cash Flow	10.44M	629.00K	-4.61M	6.64M	6.51M

Adocia Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADOCY, the sentiment is Neutral. The current price of 10.04 is below the 20-day moving average (MA) of 10.77, above the 50-day MA of 9.97, and above the 200-day MA of 6.62, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 47.30 is Neutral, neither overbought nor oversold. The STOCH value of 11.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADOCY.

Adocia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CCCC	47 Neutral	$221.50M	―	-59.98%	―	-10.57%	1.98%
ADOCY	45 Neutral	$189.77M	-16.94	306.12%	―	1882.51%	62.37%
FATE	41 Neutral	$123.40M	―	-52.11%	―	-31.23%	14.92%
ACHV	37 Underperform	$242.24M	―	-161.08%	―	―	-22.06%